Introduction {#s1}
============

Whilst over the past few decades there has been an improvement in the survival of patients in multiple domains within pediatric oncology, the prognosis for the majority of children with malignant brain tumors remains grim ([@B1]). Their poor survival can be attributed to a lack of efficacious therapies, and a limited understanding of the underlying genetic and biochemical abnormalities associated with this group of diseases, which has hindered the development of more effective and patient-specific treatment. In the past years, a number of recurrent mutations have been identified that allow for the identification of tumor subgroups with distinct biological characteristics ([@B2], [@B3]). Importantly, these molecular features have been incorporated into the new (2016) World Health Organization (WHO) classification, which now distinguishes tumor subgroups not only histologically, but also based on molecular characteristics ([@B4]). The new classification has improved the diagnosis of pediatric brain tumors, but this knowledge has not yet led to a better prognosis for pediatric brain tumor patients. In order to increase survival rates whilst decreasing treatment-related side-effects, new targeted treatments must be developed which feature subgroup-specific clinical trials, and are conducted based on the distinct underlying genetic aberrations. However, with an increasing number of tumor subgroups and consequently a decreasing number of eligible patients, it will become ever more important to test novel treatment strategies in preclinical research before proceeding to clinical trials. Representative cell lines and animal models will therefore have to be developed, representing the broad spectrum of pediatric brain tumors. To facilitate the choice of the appropriate preclinical animal model, and emphasize the need for new models that are still lacking, we here provide an overview of the currently available orthotopic xenograft models for pediatric brain tumors, divided by specific subtypes as defined by the 2016 WHO classification ([@B4]). Although multiple types of animal models are currently available for the investigation of new treatments for pediatric brain tumors *in vivo*, we will focus on patient-derived xenografts (PDXs) rather than Genetically Engineered Mouse Models (GEMMs) within which tumor-specific genetic aberrations are introduced. PDXs have been shown to have an increased reliability when reproducing the heterogeneity of the human disease, which may better reflect the therapy response in patients than GEMMs ([@B5], [@B6]). In addition, we will focus on the models that have been established by xenografting fresh patient-derived material rather than established human cancer cell lines that have adapted to growth under artificial culture conditions, and are generally considered less relevant for clinical translation due to a more homogeneous, undifferentiated histology ([@B7]--[@B9]). Finally, we will only consider intracranial/orthotopic models, as these models retain the tumor-host microenvironment which may play a role in tumor response ([@B10]), and tumor growth ([@B11]). Moreover, such orthotopic models closely mimic human metastasis and allow to study drug delivery past the blood-brain barrier ([@B5], [@B7], [@B12], [@B13]).

PDX Models {#s2}
==========

Currently available pediatric brain tumor PDXs are established by xenografting fresh tissue, freshly isolated cell suspensions, or shortly cultured neurospheres in immunosuppressed rats ([@B14]), or immunodeficient mice ([@B7], [@B15]--[@B17]). Various immunocompromised mouse strains are available, with different rates of engraftment, lifespan, and sensitivity for chemotherapy or radiation ([@B5], [@B9], [@B18]). Not all strains have been fully characterized, and it is therefore essential to understand these differences when choosing the most appropriate animal model. BALB/c mice, for example, are particularly sensitive to the effects of radiation due to an unknown autosomal recessive genetic locus ([@B19]). Therefore, immunodeficient mice on a BALB/c genetic background should not be used for studies involving radiotherapy. Similarly, SCID (severe combined immunodeficient) animals are very sensitive to γ-irradiation, as they harbor a mutation in the *Prkdc* gene, which is involved in the repair of double strand DNA breaks ([@B20]). In contrast, other strains---such as Rag1-deficient (recombination activating gene 1) mice---have been reported to survive radiation doses up to 8.5 Gray, and are considered radioresistant ([@B21]). Working with mice on defined genetic backgrounds is therefore advisable for irradiation studies. The same holds true for experiments aimed at testing therapy response when DNA damaging agents are used. The response to cisplatin, doxorubicin, 5-fluoroacil, and oxaliplatin was shown to depend on PRKDC function ([@B22]), and should therefore not be tested in SCID mice. For more targeted compounds no clear guidelines exist for the choice of mouse strain, although some differences have been reported on drug sensitivity depending on drug transporters and metabolism ([@B23]). In those cases, the choice of the most appropriate PDX model should be based on the molecular subtype of the tumor.

Aside from different responses to therapy, there are also significant differences in tumor engraftment between various strains. Generally, it is believed that the level of immunodeficiency correlates with the tumor take rate ([@B8], [@B9]); as such, the more immunocompromised mouse strains, NOD/SCID/IL2γ-receptor null (NSG) and NOS/Rag/IL2γ-receptor null (NRG), would be most suitable strains for the implantation of primary cancerous cells, stem cells or tissue ([@B9], [@B19], [@B24]). It has been reported that these models support more robust post-engraftment tumor growth compared to double-mutant mice ([@B25], [@B26]), whilst maintaining the characteristics of the original primary patient tumor ([@B27]). However, studies confirming this view have only been performed with specific PDX models for hematological forms of cancer or using subcutaneous injections of tumor cells, and no convincing assessment regarding the preferred mouse strain for pediatric brain tumors has been carried out ([@B24], [@B28]--[@B30]).

One major limitation of the use of immunocompromised mice is that the interaction between the tumor and the immune microenvironment is partially or completely lost to ensure tumor engraftment is successful ([@B5], [@B9]). Consequently, the current PDX models cannot be used to study the (tumor) immune microenvironment, or to test novel immunotherapeutic treatment strategies ([@B9]). One solution to this problem has been found in the use of humanized-xenograft models ([@B5], [@B9], [@B12], [@B18]), in which the peripheral blood or bone marrow of the patient is co-engrafted with the tumor material into mouse strains lacking mouse natural killer cell activity (for example NSG or NRG mice) ([@B9]). Although this is a promising strategy for the testing of immunotherapy in the future, no humanized-xenograft models for pediatric brain tumors have yet been described.

Besides the choice of animal strain, other factors may influence the success rate of tumor engraftment. For instance, patient tissue can be collected either at time of diagnosis (biopsy), as part of treatment (surgical resection), or *post-mortem*. The moment of tissue collection may affect the characteristics of the PDX model, as treatment can change the molecular features of the tumor ([@B31]). As such, PDX models established from samples that are retrieved before treatment may be more suitable to test new therapies that can be implemented in the initial treatment schedules, while PDX models from autopsy samples, representing the late stage of disease, may be more appropriate to study resistance mechanisms and treatment effects ([@B32]).

In addition, various methods are used for the processing of the tumor cells before injection. Although occasionally whole tumor pieces have been used for implantation ([@B33], [@B34]), the most used method to establish pediatric brain tumor PDX models, is the preparation of cell suspensions either by dissociation of neurospheres or directly from surgical specimen ([Table A1](#TA1){ref-type="table"}). Alternatively, tumor cells can be enriched for brain tumor-initiating cells (BTICs) by sorting for CD133+ cells ([@B35]), grown as an adherent layer ([@B31], [@B36]--[@B44]), transplanted in the thalamus or subcutaneously to expand the tumor cells ([@B32], [@B40], [@B45], [@B46]), or injected intracranially after serial transplantation ([@B16], [@B35], [@B40], [@B46]--[@B55]).

Although subcutaneous propagation has been shown to retain tumor characteristics and to decrease the time required for the PDX model procedure ([@B7]), no significant differences appear to exist between the direct- and indirect xenografting of tumor cells. In a head to head comparison of tumor models, generated by the injection of tumor cells derived directly from the patient and implantation of cultured cells, no variance was observed in tumorigenicity or histopathology of the xenograft ([@B32]). The authors did however find a discrepancy in survival time, with xenograft models obtained from cells in culture living longer (see [Table A1](#TA1){ref-type="table"}), correlating to a greater degree with patient survival. This discrepancy between the direct- and indirect method could originate from inequivalent numbers of injected tumor cells, or the presence of stroma and microenvironment in direct implantation.

Besides a better correlation with patient survival, indirect xenografting, encompassing a cell culture step before intracranial implantation, additionally allows for the introduction of the *Firefly luciferase* gene by lentiviral transduction, facilitating non-invasive monitoring of tumor growth by bioluminescent imaging (BLI) in preclinical therapeutic studies ([@B56]). Although a temporary culture step as an adherent monolayer may be needed for effective transduction ([@B57]), cells are generally grown as neurospheres, since spheroid cultures have been shown to have a greater degree of genetic stability compared to cells grown in attachment ([@B58]). Independent of the culture conditions or method of implantation, PDXs should always be compared to the original tumor to validate the models. Preferably this is done both histologically and by molecular analyses, e.g., by confirmation of copy number variations/tumor-specific mutations or DNA methylation profiling. Such validation is extremely important, as some studies even suggest that the presence of stroma cells in *post-mortem* tissue may generate murine tumors rather than human xenografts ([@B59], [@B60]).

The large variety of available methods and mouse strains indicates that, until recently, no clear consensus existed in the field regarding the best model set-up. However, in the past decade multiple consortia have been founded, such as the Pediatric Preclinical Testing Consortium, the Childhood Solid Tumor Network, the Children\'s Oncology Group (COG), and the European EurOPDX resource, that collect and validate PDX models to increase the reproducibility of PDX studies ([@B16]). Although currently only few pediatric PDX models are included in the abovementioned databases, these initiatives emphasize the importance of a validated set-up. Furthermore, in order to assure the quality of newly established PDX models, a PDX models Minimal Information standard (PDX-MI) has been developed that defines the minimal information regarding the clinical characteristics and the procedures of implantation in a host mouse strain ([@B31]). For all these models it will be important to validate to which extent the xenograft tumor diverges from the donor tumor, both molecularly and histologically ([@B8]). However, the provision of such data, as well as peruse of the clinical patient information, might be challenging due to patient privacy or data inaccessibility ([@B31]).

Future Perspectives {#s3}
===================

Whilst the number of available orthotopic xenograft models for pediatric brain tumor research is growing, some tumor types are still underrepresented. Models for craniopharyngioma, germinoma, embryonal tumors with multilayered rosettes (ETMR), pineoblastoma, diffuse astrocytoma, oligodendroglioma, and cancers belonging to the "other astrocytic tumors/gliomas" are scarce, and no models have currently been described for e.g., choroid plexus tumors. This paucity may be attributed to a minimal research interest into certain tumor types, the limited availability of tumor material, or a low tumor take-rate ([@B17]). Failure of tumor engraftment often occurs with the less aggressively growing (low-grade) tumors, such as pilocytic astrocytoma ([@B61]). For some of these tumor types, the use of more invading cells from a metastatic site ([@B62]), or samples from recurrent tumors might be an interesting alternative, as more aggressive tumor cells are thought to have a higher take rate *in vivo* ([@B18]). Care however needs to be taken to assure the practical use of such models, as recurrences and metastatic clones may differ from the primary tumor at diagnosis. Alternatively, more effective tumor-specific protocols may have to be developed. So far, only few comparative studies have been performed to determine the most optimal protocols per tumor type, with regard to sample size, sample processing, and mouse strain ([@B17]). In addition, the choice of animal model and experimental set-up may vary, depending on the research question; for low-grade tumors, for example, studies may be aimed at diminishing treatment-related side-effects, while survival studies will be more relevant for tumor subtypes with a poor prognosis.

Whilst appropriate PDX models for some tumor types are still missing, other pediatric brain tumor types seem to be more strongly represented. This especially holds true for models of glioblastoma, diffuse midline glioma, ependymoma, and medulloblastoma. Preclinical research in these fields is expanding, partly due to the raised interest in these tumor types, and to the increased availability of tumor material. For example, the development of autopsy protocols and the reintroduction of surgical biopsies for diffuse midline gliomas ([@B63]) has boosted preclinical research for these tumors, leading to the development of several animal models ([@B16]). Yet, more PDX models may be required for these tumor types as well, to cover different subgroups, stages, and heterogeneity of the disease. Full tumor dynamics may be captured by the collection of paired tumor samples at the time of diagnosis and at autopsy, while intratumoral heterogeneity may be covered by the sampling of multiple lesions from the same tumor in rapid autopsy protocols ([@B64]). Additional PDX models comprising the complete spectrum of the disease are needed to confirm the reproducibility of preclinical results, and to ensure clinical relevance of laboratory findings.

Despite the presence of a relatively high number of pediatric glioma models, PDXs covering *IDH1* mutations are lacking. Moreover, many described PDX models for pediatric glioma have not been molecularly characterized ([@B16], [@B35], [@B38], [@B48], [@B65]), even though mutation analysis could classify them as belonging to specific biological subgroups ([@B66]). The same holds true for ependymoma ([@B14], [@B38], [@B45], [@B46], [@B67]) and, to a lesser extent, medulloblastoma models ([@B38], [@B42]--[@B44], [@B68]). For other tumor types, such as pineoblastoma, or germ cell tumors no molecular subgroups have yet been identified. Proper model validation and characterization of the available PDXs will be essential to test new therapies, especially when targeted therapy is applied. Many of the currently available PDX models without molecular designation have been established in the early 2000s, and these models may still be useful, provided that molecular profiling is performed. This might be an option for tumor types for which less PDXs are currently available, such as the atypical teratoid rhabdoid tumors (AT/RTs), a relatively rare, but highly aggressive pediatric brain tumor with a poor survival ([@B69]), which would benefit from preclinical *in vivo* studies to ameliorate prognosis and diminish long-term sequelae. One should however keep in mind that validation of those models by comparing the molecular features of the PDX with the original tumor will often not be possible. In such cases, models may be validated by comparing RNAseq-, whole genome sequencing-, and DNA methylation profiles with cohorts of patient data to ensure their representability of the human disease.

In order to translate preclinical findings to the clinic, the proper choice of animal model and experimental set-up will be paramount. Improved PDX models may be used for personalized medicine purposes, where the predictive value of therapy for a certain patient is determined based on a personal panel of mouse tumors. However, such a personalized approach is currently hampered by the time that is needed to develop these models, costs, and the variable rate of engraftment. Alternatively, multiple tumor-specific animal models may be used to conduct so-called Mouse Clinical Trials (MCTs). MCTs use small numbers of mice per treatment arm across a large number of PDX models, resembling human clinical trials more closely than preclinical trials in which large numbers of a specific PDX model are used ([@B70]). MCTs will help researchers to understand the correlation of specific genetic factors to therapy response, and may allow to predict patient response, as well as correct patient stratification. For this reason, additional, fully characterized models need to be developed with a special focus on the poorly represented subtypes. These models may be used to determine the best therapeutic regimes for each tumor subtype to implement in standard protocols.

In summary, although progress has been made in the development of orthotopic xenograft models for pediatric brain tumors, there is a clear imbalance in the number of PDX models for different tumor types, and a high variability in methodology and animal strains used. Combined efforts of neurosurgeons, pathologists, pediatric oncologists and preclinical researchers will be needed to develop additional animal models for the design of effective therapeutic strategies.
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Overview of available orthotopic xenograft models per tumor entity, based on the 2016 WHO classification of tumors of the central nervous system.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Model name**                                       **Tumor classification**                                    **Tumor location**                         **Molecular classification**                       **Moment of tumor collection**               **Age in years (y) or months (mo) and sex donor **♀♂****   **Mouse strain and age**                           **Tumor preparation before injection**                            **Injection site**                                                                            **BLI**   **Time to tumor growth/euthanasia**    **Source**                                                                                                                   **References**
  ---------------------------------------------------- ----------------------------------------------------------- ------------------------------------------ -------------------------------------------------- -------------------------------------------- ---------------------------------------------------------- -------------------------------------------------- ----------------------------------------------------------------- --------------------------------------------------------------------------------------------- --------- -------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- ----------------
  **DIFFUSE ASTROCYTIC AND OLIGODENDROGLIAL TUMORS**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  bGB1                                                 Giant cell glioblastoma                                     Cerebrum (frontal lobe)                    ND                                                 Surgical resection                           3.6 y                                                      ND                                                 Short-term adherent cell culture                                  Right cerebral hemisphere (ML +2 mm, AP +2 mm)                                                --        ND                                     University of Birmingham                                                                                                     ([@B38])

  CCHMC-DIPG-1                                         Diffuse midline glioma, H3K27M mutant                       ND                                         H3.3K27M                                           ND                                           ND                                                         NSG, postnatal day 2                               Short-term cell culture in spheroids                              4th ventricle (AP −3 mm, DV −3 mm)                                                            \+        16--19 days                            On request (Dr. Drissi, Cincinnati Children\'s Hospital)                                                                     ([@B71])

  DIPG-PBTR3                                           Diffuse midline glioma, H3K27M mutant                       Ventral pons                               H3.3K27M                                           Autopsy                                      5 y ♂                                                      NSG, postnatal day 2                               Short-term cell culture in spheroids                              4th ventricle (AP −3 mm, DV −3 mm)                                                            \+        6 months to clinical symptoms          On request                                                                                                                   ([@B71])

  GBM-311FH                                            Glioblastoma, IDH wild-type                                 Cortex (left temporal lobe)                Hypermutator                                       Surgical resection                           10.8 y ♂                                                   NSG                                                Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −2 mm)                                    --        77--85 days                            BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  GBM-611FH                                            Glioblastoma, IDH wild-type                                 Cortex (left temporal lobe)                Hypermutator                                       Autopsy (recurrence)                         11.3 y ♂                                                   NSG                                                Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −2 mm)                                    --        79--128 days                           BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  GU-pBT-7                                             Diffuse midline glioma, H3K27M mutant                       Right hemisphere (thalamus)                H3.1K27M, EGFR/KRAS amplification, CCND deletion   Surgical resection (primary tumor)           4.2 y ♂                                                    NOD/SCID, 6--8 weeks                               Short-term adherent cell culture                                  Frontal cortex ML +2 mm, AP +1 mm, DV −2.5 mm                                                 --        120--125 days                          On request                                                                                                                   ([@B37])

  GU-pBT-10                                            Glioblastoma NOS                                            Right hemisphere (relapse)                 CDKN2A/B deletion                                  Surgical resection (recurrence)              10.4 y ♂                                                   NOD/SCID, 6--8 weeks                               Short-term adherent cell culture                                  Frontal cortex ML +2 mm, AP +1 mm, DV −2.5 mm                                                 --        215--330 days                          On request                                                                                                                   ([@B36])

  GU-pBT-15                                            Diffuse midline glioma, H3K27M mutant                       Brain stem                                 H3.3K27M                                           Surgical resection (primary tumor)           12.5 y ♀                                                   NOD/SCID, 6--8 weeks                               Short-term adherent cell culture                                  Frontal cortex ML +2 mm, AP +1 mm, DV −2.5 mm                                                 --        310--400 days                          On request                                                                                                                   ([@B36])

  GU-pBT-19                                            Diffuse midline glioma, H3K27M mutant                       Right hemisphere (thalamus)                H3.3K27M, RB deletion                              Surgical resection (primary tumor)           6.2 y ♂                                                    NOD/SCID, 6--8 weeks                               Short-term adherent cell culture                                  Frontal cortex ML +2 mm, AP +1 mm, DV −2.5 mm                                                 --        285--350 days                          On request                                                                                                                   ([@B36])

  GU-pBT-23                                            Glioblastoma NOS                                            Left hemisphere (temporal)                 PDGFRA/\                                           Surgical resection (primary tumor)           2.9 y ♀                                                    NOD/SCID, 6--8 weeks                               Short-term adherent cell culture                                  Frontal cortex ML +2 mm, AP +1 mm, DV −2.5 mm                                                 --        70--75 days                            On request                                                                                                                   ([@B37])
                                                                                                                                                              CDK4/MDM2 amplification                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  GU-pBT-28                                            Glioblastoma NOS                                            Pons (cerebellopontine angle)              EGFR amplification, NF1/\                          Surgical resection (primary tumor)           11.1 y ♀                                                   NOD/SCID, 6--8 weeks                               Short-term adherent cell culture                                  Frontal cortex ML +2 mm, AP +1 mm, DV −2.5 mm                                                 --        130--155 days                          On request                                                                                                                   ([@B37])
                                                                                                                                                              CDKN2A/B deletion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  HSJD-DIPG-07                                         Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M, ACVR1 R206H                              Autopsy                                      9.9 y ♂                                                    Athymic nude Foxn1nu, 6 weeks                      Short-term cell culture in spheroids                              Pons (ML +1 mm, AP −0.8 mm, DV −4.5 mm)                                                       \+        38--74 days                            On request (Dr. Montero-Carcaboso, Barcelona)                                                                                ([@B73])

  Ibs-W0128DIPG/\                                      Glioblastoma, IDH wild-type                                 Pons                                       H3 WT, ACVR1 G328V, PIK3CA Q546K                   Autopsy                                      8.5 y ♂                                                    NOD/SCID                                           Cell suspension from surgical specimen                            Pons (DV −5.2 mm)                                                                             --        37--70 days                            On request (Dr. Li, Houston)                                                                                                 ([@B47])
  Li-F                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  IC-1128GBM                                           Glioblastoma NOS                                            Cerebrum                                   ND                                                 Surgical resection (recurrence)              8.6 y ♂                                                    Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −3 mm)                                    --        150--180 days                          On request                                                                                                                   ([@B16])

  IC-1406 GBM                                          Glioblastoma NOS                                            Cerebrum                                   ND                                                 Surgical resection                           5 y ♀                                                      Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −3 mm)                                    --        67--79 days                            On request                                                                                                                   ([@B48])

  IC-1502 GBM                                          Giant cell glioblastoma                                     Cerebrum                                   ND                                                 Surgical resection                           4.6 y ♀                                                    Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −3 mm)                                    --        77--96 days                            On request                                                                                                                   ([@B48])

  IC-1621 GBM                                          Glioblastoma NOS                                            Cerebrum                                   ND                                                 Surgical resection                           6 y ♂                                                      Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −3 mm)                                    --        125--160 days                          On request                                                                                                                   ([@B48])

  IC-2305 GBM                                          Glioblastoma NOS                                            Cerebrum                                   ND                                                 Surgical resection                           9 y ♀                                                      Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −3 mm)                                    --        ND                                     On request                                                                                                                   ([@B48])

  IC-3704 GBM                                          Glioblastoma NOS                                            Cerebrum                                   ND                                                 Surgical resection                           12 y ♂                                                     Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −3 mm)                                    --        ND                                     On request                                                                                                                   ([@B35])

  IC-3752 GBM                                          Glioblastoma NOS                                            Left hemisphere (frontal)                  H3 WT                                              Surgical resection (recurrence)              4 y ♀                                                      Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −3 mm)                                    --        ND                                     On request                                                                                                                   ([@B35])

  IC-4687GBM                                           Glioblastoma NOS                                            Right hemisphere (thalamus)                H3 WT                                              Surgical resection (at diagnosis)            7 y ♂                                                      NOD/SCID, 6--8 weeks                               Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −3 mm)                                    --        40--117 days                           On request                                                                                                                   ([@B74])

  IC-R0315GBM                                          Glioblastoma NOS                                            Left hemisphere (parietal)                 H3 WT                                              Autopsy                                      9 y ♀                                                      NOD/SCID, 6--8 weeks                               Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −3 mm)                                    --        35--47 days                            On request                                                                                                                   ([@B74])

  ICb-1227AA                                           Anaplastic astrocytoma NOS (secondary)                      Cerebellum                                 ND                                                 Surgical resection                           16.9 y ♀                                                   Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Cerebellum (ML +1 mm, AP −1 mm, DV −3 mm)                                                     --        62--80 days                            On request                                                                                                                   ([@B16])

  JHH-DIPG-01                                          Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M                                           Autopsy                                      8 y ♂                                                      Athymic nu/nu                                      Short-term cell culture in spheroids                              Brainstem (ML +1 mm, AP −5 mm, DV −3.5 mm)                                                    --        230--245 days                          On request                                                                                                                   ([@B75])

  NEM273                                               Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.1K27M, ACVR1 G328E                              Biopsy                                       4.6 y ♂                                                    Athymic nude, 4--6 weeks                           Short-term adherent cell culture                                  Pons (ML +1 mm, AP −1 mm, DV −5 mm)                                                           \+        220--258 days                          On request                                                                                                                   ([@B32])

  NEM285                                               Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M, TP53 A159V                               Biopsy                                       7.1 y ♂                                                    Athymic nude, 4--6 weeks                           Short-term adherent cell culture                                  Pons (ML +1 mm, AP −1 mm, DV −5 mm)                                                           \+        174--224 days                          On request                                                                                                                   ([@B32])

                                                                                                                                                                                                                                                                                                                                                                            Cell suspension from surgical specimen                            Thalamus/Pons (ML +2 mm, AP −3 mm, DV −3.5 mm/ML +1 mm, AP −1 mm, DV −5 mm)                   --        117--129 days                          On request                                                                                                                   

  NEM289                                               Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.2K27M, TP53 W146\*                              Biopsy                                       4.7 y ♂                                                    Athymic nude, 4--6 weeks                           Short-term adherent cell culture                                  Pons (ML +1 mm, AP −1 mm, DV −5 mm)                                                           \+        228--270 days                          On request                                                                                                                   ([@B32])

                                                                                                                                                                                                                                                                                                                                                                            Cell suspension from surgical specimen                            Thalamus/Pons (ML +2 mm, AP −3 mm, DV −3.5 mm/ML +1 mm, AP −1 mm, DV −5 mm)                   --        93--111 days                           On request                                                                                                                   

  NEM290                                               Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M, TP53 R175H                               Biopsy                                       11.6 y ♀                                                   Athymic nude, 4--6 weeks                           Short-term adherent cell culture                                  Pons (ML +1 mm, AP −1 mm, DV −5 mm)                                                           \+        131--139 days                          On request                                                                                                                   ([@B32])

                                                                                                                                                                                                                                                                                                                                                                            Cell suspension from surgical specimen                            Thalamus/Pons (ML +2 mm, AP −3 mm, DV −3.5 mm/ML +1 mm, AP −1 mm, DV −5 mm)                   --        68--92 days                            On request                                                                                                                   

  NEM292                                               Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M, TP53 P151T                               Biopsy                                       5.2 y ♀                                                    Athymic nude, 4--6 weeks                           Short-term adherent cell culture                                  Pons (ML +1 mm, AP −1 mm, DV −5 mm)                                                           \+        61--73 days                            On request                                                                                                                   ([@B32])

  NEM325                                               Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M                                           Biopsy                                       5.5 y ♀                                                    Athymic nude, 4--6 weeks                           Cell suspension from surgical specimen                            Thalamus/Pons (ML +2 mm, AP −3 mm, DV −3.5 mm/ML +1 mm, AP −1 mm, DV −5 mm)                   --        87--111 days                           On request                                                                                                                   ([@B32])

  NEM328                                               Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.1K27M, ACVR1 G328V                              Biopsy                                       3.5 y ♀                                                    Athymic nude, 4--6 weeks                           Short-term adherent cell culture                                  Pons (ML +1 mm, AP −1 mm, DV −5 mm)                                                           \+        239--295 days                          On request                                                                                                                   ([@B32])

                                                                                                                                                                                                                                                                                                                                                                            Cell suspension from surgical specimen                            Thalamus/Pons (ML +2 mm, AP −3 mm, DV −3.5 mm/ML +1 mm, AP −1 mm, DV −5 mm)                   --        147--211 days                          On request                                                                                                                   

  NEM335                                               Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M, TP53 R248Q                               Biopsy                                       6.2 y ♂                                                    Athymic nude, 4--6 weeks                           Cell suspension from surgical specimen                            Thalamus/Pons (ML +2 mm, AP −3 mm, DV −3.5 mm/ML +1 mm, AP −1 mm, DV −5 mm)                   --        126--134 days                          On request                                                                                                                   ([@B32])

  NEM347                                               Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M, TP53 R273C                               Biopsy                                       9.1 y ♂                                                    Athymic nude, 4--6 weeks                           Cell suspension from surgical specimen                            Thalamus/Pons (ML +2 mm, AP −3 mm, DV −3.5 mm/ML +1 mm, AP −1 mm, DV −5 mm)                   --        117--125 days                          On request                                                                                                                   ([@B32])

  NEM353                                               Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M                                           Biopsy                                       6.5 y ♀                                                    Athymic nude, 4--6 weeks                           Cell suspension from surgical specimen                            Thalamus/Pons (ML +2 mm, AP −3 mm, DV −3.5 mm/ML +1 mm, AP −1 mm, DV −5 mm)                   --        81 days                                On request                                                                                                                   ([@B32])

  nOLIG1                                               Oligodendroglioma NOS                                       Cerebrum (right fronto temporo-parietal)   ND                                                 Surgical resection                           6.5 y                                                      ND                                                 Short-term adherent cell culture                                  Right cerebral hemisphere (ML +2 mm, AP +2 mm)                                                --        ND                                     Children\'s Brain Tumour Research Centre, Nottingham                                                                         ([@B38])

  PBT-01FH                                             Diffuse midline glioma, H3K27M mutant                       Cortex, bilateral thalamic                 H3.1K27M                                           Autopsy (recurrence)                         5 y ♀                                                      NSG                                                Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −2 mm)                                    --        89--116 days                           BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  PBT-02FH                                             Anaplastic astrocytoma, NOS                                 Cortex                                     CDK4 amplification, FGFR1 mutation                 Autopsy (recurrence)                         14.8 y ♂                                                   NSG                                                Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −2 mm)                                    --        52--121 days                           BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  PBT-05FH                                             Glioblastoma, IDH wild-type                                 Cortex, right frontal                      Myc amplification                                  Surgical resection (recurrence)              9.1 y ♀                                                    NSG                                                Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −2 mm)                                    --        37--42 days                            BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  PBT-06FH                                             Glioblastoma, IDH wild-type                                 Cortex, right frontoparietal               p 53 mutation, CDK4 amplification                  Autopsy (recurrence)                         15.9 y ♀                                                   NSG                                                Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −2 mm)                                    --        131--326 days                          BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  QCTB-R059                                            Diffuse midline glioma, H3K27M mutant                       Thalamus                                   H3.3K27M                                           Surgical resection                           10.4 y ♀                                                   NSG, postnatal day 35                              Short-term cell culture in spheroids                              Thalamus (ML +0.8 mm, AP −1 mm, DV −3.5 mm)                                                   \+        12--14 days                            Queensland Children\'s Medical Research Institute, Brisbane                                                                  ([@B76])

  SF7761                                               Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M (hTERT modified)                          Biopsy                                       6 y ♀                                                      Athymic nu/nu, 6 weeks                             Short-term cell culture in spheroids                              Pontine tegmentum (ML +1.5 mm, DV −5 mm)                                                      \+        106--130 days                          On request                                                                                                                   ([@B77])

  SF8628                                               Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M, p53 mutation                             Biopsy                                       3 y ♀                                                      Athymic nu/nu, 5 weeks                             Short-term adherent cell culture                                  Pontine tegmentum (ML +1.5 mm, DV −5 mm)                                                      \+        66--70 days                            On request                                                                                                                   ([@B39])

  SU-pcGBM1                                            Glioblastoma NOS                                            Cortex                                     ND                                                 ND                                           ND                                                         NOD/SCID, 6--8 weeks                               Short-term cell culture in spheroids                              Left hemisphere (ML−2 mm, AP −2 mm, DV −3.5 mm)                                               \+        ND                                     On request (Dr. Monje, Stanford)                                                                                             ([@B65])

  SU-pcGBM2                                            Glioblastoma, IDH wild-type                                 Frontal lobe                               P53 mutation, EGFR amplification                   Biopsy                                       15 y ♂                                                     NSG, postnatal day 35                              Short-term cell culture in spheroids                              Right hemisphere (ML +0.5 mm, AP +1 mm, DV −1.75 mm)                                          \+        126--163 days                          On request                                                                                                                   ([@B11])

  SU-DIPG-I                                            Anaplastic astrocytoma, IDH wiltd-type                      Pons                                       H3 WT, p53 mutation                                Autopsy                                      5 y ♂                                                      NSG, postnatal day 2                               Short-term cell culture in spheroids                              4th ventricle/lateral ventricles (ML +1 mm, AP −3 mm, DV −3 mm/ML +1 mm, AP +2 mm, DV −2 mm   --        26 weeks to clinical symptoms          On request (Dr. Monje, Stanford)                                                                                             ([@B78])

  SU-DIPG-VI                                           Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M, p53 mutation                             Autopsy                                      7 y ♀                                                      NSG, postnatal day 2                               Short-term cell culture in spheroids                              4th ventricle/pons (AP −3 mm, DV −3 mm)                                                       \+        ≤2 months (BLI)                        On request                                                                                                                   ([@B47])

  SU-DIPG-XIIIP\*                                      Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M                                           Autopsy                                      6 y ♀                                                      NSG, postnatal day 43                              Short-term cell culture in spheroids                              4th ventricle/pons (ML +0.8 mm, AP −0.5 mm, DV −5 mm)                                         \+        19--28 days                            On request                                                                                                                   ([@B79])

  SU-DIPG-XIIIFL                                       Diffuse midline glioma, H3K27M mutant                       Frontal lobe metastasis                    H3.3K27M                                           Autopsy                                      6 y ♀                                                      NSG, postnatal day 2                               Short-term cell culture in spheroids                              4th ventricle/pons (ML +0.8 mm, AP −0.5 mm, DV −5 mm)                                         \+        ND                                     On request                                                                                                                   ([@B79])

  SU-DIPG-XIX                                          Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M                                           Autopsy                                      2 y ♂                                                      NSG, postnatal day 35                              Short-term cell culture in spheroids                              Pons (ML +1 mm, AP −0.8 mm, DV −5 mm)                                                         \+        ND                                     On request                                                                                                                   ([@B80])

  SU-pSCG-1                                            Diffuse midline glioma, H3K27M mutant                       spinal cord                                H3.3K27M                                           Autopsy                                      12 y ♂                                                     NSG, postnatal day 35                              Short-term cell culture in spheroids                              Medulla (ML +0.7 mm, AP −3.5 mm, DV −4.5 mm)                                                  \+        ND                                     On request (Dr. Monje, Stanford)                                                                                             ([@B76])

  TT10603                                              Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M, TP53 R141C                               Surgical resection                           7 y ♂                                                      NSG                                                Short-term adherent cell culture                                  Brainstem (ML +1 mm, AP −1.5 mm, DV −4.5 mm)                                                  --        172 days to onset (MRI)                On request                                                                                                                   ([@B40])

  TT10630                                              Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M, PPM1D S516X                              Biopsy                                       4 y ♀                                                      NSG                                                Short-term adherent cell culture                                  Brainstem (ML +1 mm, AP −1.5 mm, DV −4.5 mm)                                                  --        186 days to onset (MRI)                On request                                                                                                                   ([@B40])

  TT10714                                              Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M, PPM1D C478X                              Surgical resection                           6 y ♀                                                      NSG                                                Short-term adherent cell culture                                  Brainstem (ML +1 mm, AP −1.5 mm, DV −4.5 mm)                                                  --        155 days to onset (MRI)                On request                                                                                                                   ([@B40])

  VUMC-DIPG-F                                          Diffuse midline glioma, H3K27M mutant                       Pons                                       H3.3K27M                                           Biopsy                                       7 y ♂                                                      FVB athymic, 6--8 weeks                            Short-term cell culture in spheroids                              Pons (ML +0.8 mm, AP −1 mm, DV −4.5 mm)                                                       \+        120--179 days                          On request                                                                                                                   ([@B81])

  **OTHER ASTROCYTIC TUMORS**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  IC-3635 PXA                                          Pleomorphic xanthoastrocytoma (grade II)                    Left temporal lobe                         BRAF V600E, CDKN2A deletion                        Surgical resection                           10 y ♀                                                     NOD/SCID, 6--8 weeks                               Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −3 mm)                                    --        175--255 days                          On request                                                                                                                   ([@B82])

  **EPENDYMAL TUMORS**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  BT-44                                                Anaplastic ependymoma                                       Posterior fossa                            ND                                                 ND                                           2 y ♀                                                      Athymic nu/nu, 5--6 weeks                          Cell suspension from surgical specimen                            Caudate nucleus                                                                               --        100--155 days                          On request                                                                                                                   ([@B46])

  BT-57                                                Anaplastic ependymoma                                       Posterior fossa (focal)                    ND                                                 ND                                           10 mo ♂                                                    Athymic nu/nu, 5--6 weeks                          Cell suspension from surgical specimen                            Caudate nucleus                                                                               --        100--155 days                          On request                                                                                                                   ([@B46])

  D528 EP-X                                            Ependymoma                                                  Posterior fossa                            ND                                                 Biopsy                                       2.5 y ♀                                                    BALB/c nu/nu, 3--4 weeks                           Cell suspension from surgical specimen                            Right cerebral hemisphere                                                                     --        ± 85 days                              On request                                                                                                                   ([@B67])

  D612 EP-X                                            Ependymoma                                                  Posterior fossa                            ND                                                 Biopsy                                       1.1 y ♀                                                    BALB/c nu/nu, 3--4 weeks                           Cell suspension from surgical specimen                            Right cerebral hemisphere                                                                     --        ± 72.5 days                            On request                                                                                                                   ([@B67])

  E520-PF1                                             Ependymoma                                                  Infratentorial                             A/CIMP (+)                                         Surgical resection                           ND                                                         NSG 8--12 weeks                                    Short-term adherent cell culture                                  Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −3 mm)                                    \+        30--59 days                            On request                                                                                                                   ([@B41])

  EPD-210FH                                            Anaplastic ependymoma                                       Posterior fossa                            PFA                                                Autopsy (recurrence)                         10 y ♂                                                     NSG                                                Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −2 mm)                                    --        75--103 days                           BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  EPD-613FH                                            Ependymoma, RELA fusion positive (grade III)                ND                                         RELA                                               Surgical resection (recurrence)              16 y ♂                                                     NSG                                                Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −2 mm)                                    --        137--223 days                          BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  EPD-710FH                                            Anaplastic ependymoma                                       Posterior fossa                            PFA                                                Surgical resection                           2.8 y ♂                                                    NSG                                                Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −2 mm)                                    --        115--326 days                          BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  EPN1                                                 Anaplastic ependymoma                                       Posterior fossa                            ND                                                 Surgical resection                           ND                                                         Wistar Rat, treated with immunosuppressant drugs   Short-term adherent cell culture                                  3rd ventricle (ML+1.4 mm, AP +0.8 mm, DV −3.8 mm)                                             FL        ≤45 days (X-ray/fluorescent imaging)   On request                                                                                                                   ([@B14])

  EPN2                                                 Anaplastic ependymoma                                       Posterior fossa                            ND                                                 Surgical resection                           ND                                                         Wistar Rat, treated with immunosuppressant drugs   Short-term adherent cell culture                                  3rd ventricle (ML+1.4 mm, AP +0.8 mm, DV −3.8 mm)                                             FL        ≤45 days (X-ray/fluorescent imaging)   On request                                                                                                                   ([@B14])

  EPN3                                                 Anaplastic ependymoma                                       Posterior fossa                            ND                                                 Surgical resection                           ND                                                         Wistar Rat, treated with immunosuppressant drugs   Short-term adherent cell culture                                  3rd ventricle (ML+1.4 mm, AP +0.8 mm, DV −3.8 mm)                                             FL        ≤45 days (X-ray/fluorescent imaging)   On request                                                                                                                   ([@B14])

  EPN4                                                 Anaplastic ependymoma                                       Posterior fossa                            ND                                                 Surgical resection                           ND                                                         Wistar Rat, treated with immunosuppressant drugs   Short-term adherent cell culture                                  3rd ventricle (ML+1.4 mm, AP +0.8 mm, DV −3.8 mm)                                             FL        ≤45 days (X-ray/fluorescent imaging)   On request                                                                                                                   ([@B14])

  EPN5                                                 Anaplastic ependymoma                                       Posterior fossa                            ND                                                 Surgical resection                           ND                                                         Wistar Rat, treated with immunosuppressant drugs   Short-term adherent cell culture                                  3rd ventricle (ML+1.4 mm, AP +0.8 mm, DV −3.8 mm)                                             FL        ≤45 days (X-ray/fluorescent imaging)   On request                                                                                                                   ([@B14])

  EPP                                                  Ependymoma                                                  4th ventricle                              SEC61G-EGFR gene fusion (subclone)                 Surgical resection (recurrence)              3.2 y ♂                                                    CD1 nu/nu, 5 weeks                                 Short-term cell culture in spheroids                              4th ventricle (ML +0.2 mm, AP −6 mm, DV −4 mm)                                                --        70--104 days                           On request                                                                                                                   ([@B45])

  EPV                                                  Ependymoma                                                  Posterior fossa                            ND                                                 Surgical resection (recurrence)              1.9 y ♂                                                    CD1 nu/nu, 5 weeks                                 Short-term cell culture in spheroids                              4th ventricle (ML +0.2 mm, AP −6 mm, DV −4 mm)                                                --        68--149 days                           On request                                                                                                                   ([@B45])

  IC-1425EPN                                           Ependymoma, RELA fusion positive (grade III)                supratentorial                             C11orf95-RELA fusion                               Surgical resection (recurrence)              9 y ♂                                                      Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −3 mm)                                    --        85--180 days                           On request                                                                                                                   ([@B50])

  nEPN1                                                Ependymoma RELA fusion positive (grade II)                  supratentorial (right parietal)            C11orf95-RELA fusion                               Surgical resection (recurrence)              13.5 y ♂                                                   ND                                                 Short-term adherent cell culture                                  Right cerebral hemisphere (ML +2 mm, AP +2 mm)                                                --        ND                                     Children\'s Brain Tumour Research Centre, Nottingham                                                                         ([@B38])

  nEPN2                                                Ependymoma                                                  4th ventricle                              ND                                                 Surgical resection                           3.4 y                                                      ND                                                 Short-term adherent cell culture                                  Right cerebral hemisphere (ML +2 mm, AP +2 mm)                                                --        ND                                     Children\'s Brain Tumour Research Centre, Nottingham                                                                         ([@B38])

  **TUMORS OF THE PINEAL REGION**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  PBT-08FH                                             Pineoblastoma                                               Pineal region                              Drosha (splice site and splice site mutation)      Surgical resection                           11.2 y ♀                                                   NSG                                                Cell suspension from surgical specimen                            Right cerebellum (ML +2 mm, AP −2 mm, DV −2 mm)                                               --        245 days                               BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  Pineo-113FH                                          Pineoblastoma                                               ND                                         ND                                                 Surgical resection                           8 y ♂                                                      NSG                                                Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −2 mm)                                    --        162--301 days                          BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  **EMBRYONAL TUMORS---MEDULLOBLASTOMA**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  BO-101                                               Medulloblastoma, NOS                                        Cerebellum                                 ND                                                 Surgical resection                           9 y ♂                                                      Athymic nu/nu, 3--4 weeks                          Short-term adherent cell culture                                  Right cerebral hemisphere                                                                     --        ND                                     On request                                                                                                                   ([@B42])

  CHLA-01-MED = CRL-3021                               Medulloblastoma                                             Posterior fossa                            Non WNT/non SHH Group 4, Myc amp                   Surgical resection (at diagnosis)            8 y ♂                                                      NOD/SCID 4--6 weeks                                Short-term cell culture in spheroids                              Right cuadate/putamen (ML +2 mm, AP +0.5 mm, DV −3.3 mm)                                      --        44 days to onset                       ATCC ([www.ATCC.org](http://www.ATCC.org))                                                                                   ([@B83])

  CHLA-259                                             Medulloblastoma, large cell/anaplastic                      Posterior fossa (4th ventricle)            ND                                                 Surgical resection (at diagnosis)            14 y ♂                                                     NOD/SCID 4--6 weeks                                Short-term adherent cell culture                                  Right cuadate/putamen (ML +2 mm, AP +0.5 mm, DV −3.3 mm)                                      --        39--77 days                            CCR (children cell line repository---[www.cells.org](http://www.cells.org))                                                  ([@B43])

  DMB006                                               Medulloblastoma                                             ND                                         Non WNT/non SHH Group 4                            Surgical resection                           ND                                                         NSG                                                Cell suspension from surgical specimen                            Cerebellum                                                                                    --                                               On request                                                                                                                   ([@B53])

  DMB012                                               Medulloblastoma, desmoplastic                               ND                                         SHH                                                ND                                           3 y ♀                                                      NSG                                                Cell suspension from surgical specimen                            Cerebellum                                                                                    \+        61--69 days                            On request                                                                                                                   ([@B52])

  HD-MB03                                              Medulloblastoma, large cell/anaplastic                      4th ventricle                              Non WNT/non SHH Group 3, Myc amp                   Surgical resection                           3 y ♂                                                      CB17-SCID                                          Short-term semi-adherent cell culture                             Left cerebellar hemisphere (ML−1.5 mm, AP −7 mm, DV −2 mm)                                    --        ≤29 days (MRI)                         On request                                                                                                                   ([@B84])

  ICb-984MB                                            Medulloblastoma, anaplastic                                 Cerebellum                                 SHH                                                Surgical resection                           7.8 y ♀                                                    Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebellum (ML +1 mm, AP −1 mm, DV −3 mm)                                               --        65--93 days                            On request                                                                                                                   ([@B16])

  ICb-1078MB                                           Medulloblastoma, anaplastic                                 Cerebellum                                 Non WNT/non SHH Group 4                            Surgical resection                           11.7 y ♂                                                   Rag2/SCID, 5--7 weeks                              Cell suspension from surgical specimen                            Cerebellum                                                                                    --        ND                                     On request                                                                                                                   ([@B85])

  ICb-1140MB                                           Medulloblastoma, anaplastic                                 Cerebellum                                 WNT                                                Surgical resection                           6 y ♂                                                      Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Cerebellum                                                                                    --        ND                                     On request                                                                                                                   ([@B49])

  ICb-1192MB                                           Medulloblastoma, classic                                    Cerebellum                                 WNT                                                Surgical resection                           12.4 y ♂                                                   Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebellum (ML +1 mm, AP −1 mm, DV −3 mm)                                               --        75--95 days                            On request                                                                                                                   ([@B16])

  ICb-1197MB                                           Medulloblastoma, nodular                                    Cerebellum                                 Non WNT/non SHH Group 3                            Surgical resection                           5 y ♂                                                      Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebellum (ML +1 mm, AP −1 mm, DV −3 mm)                                               --        272--305 days                          On request                                                                                                                   ([@B16])

  ICb-1299MB                                           Medulloblastoma, anaplastic                                 Cerebellum                                 Non WNT/non SHH Group 3                            Surgical resection                           2.8 y ♀                                                    Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebellum (ML +1 mm, AP −1 mm, DV −3 mm)                                               --        108--125 days                          On request                                                                                                                   ([@B16])

  ICb-1338MB                                           Medulloblastoma, nodular                                    Cerebellum                                 SHH                                                Surgical resection                           0.5 y ♂                                                    Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebellum (ML +1 mm, AP −1 mm, DV −3 mm)                                               --        140--203 days                          On request                                                                                                                   ([@B16])

  ICb-1487MB                                           Medulloblastoma, classic                                    Cerebellum                                 Non WNT/non SHH Group 4                            Surgical resection                           6.9 y ♂                                                    Rag2/SCID, 5--7 weeks                              Cell suspension from surgical specimen                            Cerebellum                                                                                    --        ND                                     On request                                                                                                                   ([@B85])

  ICb-1494MB                                           Medulloblastoma, anaplastic                                 Cerebellum                                 Non WNT/non SHH Group 3                            Surgical resection                           5.2 y ♀                                                    Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebellum (ML +1 mm, AP −1 mm, DV −3 mm)                                               --        55--105 days                           On request                                                                                                                   ([@B16])

  ICb-1572MB                                           Medulloblastoma, large cell                                 Cerebellum                                 Non WNT/non SHH Group 3                            Surgical resection                           14.8 y ♂                                                   Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebellum (ML +1 mm, AP −1 mm, DV −3 mm)                                               --        40--82 days                            On request                                                                                                                   ([@B16])

  ICb-1595MB                                           Medulloblastoma, anaplastic                                 Cerebellum                                 Non WNT/non SHH Group 3                            Surgical resection                           1.2 y ♂                                                    Rag2/SCID, 5--7 weeks                              Cell suspension from surgical specimen                            Cerebellum                                                                                    --        ND                                     On request                                                                                                                   ([@B85])

  ICb-Z61109MB                                         Medulloblastoma, anaplastic                                 Cerebellum                                 ND                                                 Surgical resection                           7 y ♂                                                      Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebellum (ML +1 mm, AP −1 mm, DV −3 mm)                                               --        ND                                     On request                                                                                                                   ([@B68])

  ICb-J1017MB                                          Medulloblastoma, anaplastic                                 Cerebellum                                 Non WNT/non SHH Group 3                            Surgical resection                           9 y ♂                                                      Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebellum (ML +1 mm, AP −1 mm, DV −3 mm)                                               --        ND                                     On request                                                                                                                   ([@B68])

  MB3W1                                                Medulloblastoma, anaplastic                                 4th ventricle                              Non WNT/non SHH Group 3, Myc amplification         Surgical resection                           1.8 y ♂                                                    NOD/SCID, 10--13 weeks                             Short-term cell culture in spheroids                              Right cerebellum                                                                              \+        28--55 days                            On request                                                                                                                   ([@B86])

  MB-LU-181                                            Medulloblastoma                                             ND                                         Non WNT/non SHH Group 3                            Surgical resection                           4 y ♂                                                      NOD/SCID, 8 weeks                                  Short-term cell culture in spheroids                              Right cerebellum (ML +1 mm, AP −2 mm, DV −2.5 mm)                                             --        70--126 days                           On request                                                                                                                   ([@B87])

  Med-113FH                                            Medulloblastoma, large cell/anaplastic                      Cerebellum                                 SHH                                                Surgical resection                           9.9 y ♂                                                    NSG                                                Cell suspension from surgical specimen                            Right cerebellum (ML +2 mm, AP −2 mm, DV −2 mm)                                               --        72--112 days                           BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  Med-114FH                                            Medulloblastoma, large cell/anaplastic                      Cerebellum                                 Non WNT/non SHH Group 3, Myc amplification         Surgical resection                           6.6 y ♀                                                    NSG                                                Cell suspension from surgical specimen                            Right cerebellum (ML +2 mm, AP −2 mm, DV −2 mm)                                               --        31--60 days                            BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  Med-1512FH                                           Medulloblastoma, desmoplastic                               Cerebellum                                 Non WNT/non SHH Group 4                            Surgical resection                           6 y ♀                                                      NSG                                                Cell suspension from surgical specimen                            Right cerebellum (ML +2 mm, AP −2 mm, DV −2 mm)                                               --        124--226 days                          BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  Med-1712FH                                           Medulloblastoma, desmoplastic                               Cerebellum                                 SHH                                                Surgical resection                           4.9 y ♂                                                    NSG, 6--10 week                                    Cell suspension from surgical specimen                            Right cerebellum (ML +2 mm, AP −2 mm, DV −2 mm)                                               --        86--157 days                           BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B53])

  Med-1911FH                                           Medulloblastoma, large cell/anaplastic                      Cerebellum                                 Non WNT/non SHH Group 3, Myc amplification         Surgical resection                           3.5 y ♀                                                    NSG                                                Cell suspension from surgical specimen                            Right cerebellum (ML +2 mm, AP −2 mm, DV −2 mm)                                               --        55--128 days                           BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  Med-210FH                                            Medulloblastoma (with myogenic differentiation)             Cerebellum                                 Non WNT/non SHH Group 3                            Surgical resection                           5.2 y ♀                                                    NSG                                                Cell suspension from surgical specimen                            Right cerebellum (ML +2 mm, AP −2 mm, DV −2 mm)                                               --        18--224 days                           BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  Med-211FH                                            Medulloblastoma, classic                                    Cerebellum                                 Non WNT/non SHH Group 3, Myc amplification         Surgical resection                           2.8 y ♂                                                    NSG 6--8 weeks                                     Cell suspension from surgical specimen (serial transplantation)   Right cerebellum (ML +2 mm, AP −2 mm, DV −3 mm)                                               --        42--64 days                            BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B51])

  Med-2112FH                                           Medulloblastoma, large cell/anaplastic                      Cerebellum                                 Non WNT/non SHH Group 3, Myc amplification         Surgical resection                           7 y ♂                                                      NSG                                                Cell suspension from surgical specimen                            Right cerebellum (ML +2 mm, AP −2 mm, DV −2 mm)                                               --        52--91 days                            BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  Med-2312FH                                           Medulloblastoma, classic                                    Cerebellum                                 Non WNT/non SHH Group 4                            Surgical resection                           2.8 y ♀                                                    NSG                                                Cell suspension from surgical specimen                            Right cerebellum (ML +2 mm, AP −2 mm, DV −2 mm)                                               --        105--153 days                          BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  Med-314FH                                            Medulloblastoma, classic                                    Cerebellum                                 SHH                                                Surgical resection (recurrence)              10 y ♀                                                     NSG                                                Cell suspension from surgical specimen                            Right cerebellum (ML +2 mm, AP −2 mm, DV −2 mm)                                               --        56--77 days                            BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  Med-411FH                                            Medulloblastoma, large cell/anaplastic                      Cerebellum                                 Non WNT/non SHH Group 3                            Surgical resection                           3 y ♂                                                      NSG, 6--10 week                                    Cell suspension from surgical specimen                            Right cerebellum (ML +2 mm, AP −2 mm, DV −2 mm)                                               \+        29--39 days                            BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B53])

  Med-511FH                                            Medulloblastoma                                             Cerebellum                                 Non WNT/non SHH Group 3, Myc amplification         Surgical resection (primary tumor)           ND                                                         CD1 nu/nu                                          Cell suspension from surgical specimen                            Cortex                                                                                        \+        62--68 days                            on request (Dr. Olson, Fred Hutch)                                                                                           ([@B54])

  Med-610FH                                            Medulloblastoma, large cell/anaplastic                      Cerebellum                                 Non WNT/non SHH Group 4                            Surgical resection                           5.3 y ♂                                                    NSG                                                Cell suspension from surgical specimen                            Right cerebellum (ML +2 mm, AP −2 mm, DV −2 mm)                                               --        148--187 days                          BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  Med-813FH                                            Medulloblastoma, classic                                    Cerebellum                                 SHH                                                Surgical resection                           2.6 y ♂                                                    NSG                                                Cell suspension from surgical specimen                            Right cerebellum (ML +2 mm, AP −2 mm, DV −2 mm)                                               --        32--78 days                            BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  Med-913FH                                            Medulloblastoma, classic                                    Cerebellum                                 WNT                                                Surgical resection                           7.5 y ♀                                                    NSG                                                Cell suspension from surgical specimen                            Right cerebellum (ML +2 mm, AP −2 mm, DV −2 mm)                                               --        175--415 days                          BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  nMED1                                                Medulloblastoma, NOS                                        Cerebellum                                 ND                                                 Surgical resection                           3.4 y                                                      ND                                                 Short-term adherent cell culture                                  Right cerebral hemisphere (ML +2 mm, AP +2 mm)                                                --        ND                                     Children\'s Brain Tumour Research Centre, Nottingham                                                                         ([@B38])

  nMED2                                                Medulloblastoma, NOS                                        Frontal bilateral (metastasis)             ND                                                 Surgical resection (recurrence)              10.6 y                                                     ND                                                 Short-term adherent cell culture                                  Right cerebral hemisphere (ML +2 mm, AP +2 mm)                                                --        ND                                     Children\'s Brain Tumour Research Centre, Nottingham                                                                         ([@B38])

  PBT-07FH                                             Medulloblastoma                                             ND                                         Non WNT/non SHH Group 3                            Surgical resection                           3.5 y ♀                                                    NSG                                                Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −2 mm)                                    --        67--169 days                           BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  RCMB18                                               Medulloblastoma, anaplastic                                 ND                                         SHH                                                Surgical resection                           7 y ♂                                                      NSG 6--8 weeks                                     Cell suspension from surgical specimen                            Cerebellum                                                                                    \+        34--58 days                            on request (Dr. Wechsler-Reya, Sanford-Burnham medical Discovery institute)                                                  ([@B52])

  RCMB28                                               Medulloblastoma                                             ND                                         Non WNT/non SHH Group 3                            ND                                           ND                                                         NSG 6--86--8 weeks                                 Cell suspension from surgical specimen                            Cerebellum                                                                                    --        ND                                     On request                                                                                                                   ([@B53])

  RCMB32                                               Medulloblastoma                                             ND                                         SHH                                                ND                                           ND                                                         NSG 6--8 weeks                                     Cell suspension from surgical specimen                            Cerebellum                                                                                    --        ND                                     On request                                                                                                                   ([@B53])

  SU-MB-02                                             Medulloblastoma, large cell/anaplastic                      ND                                         Non WNT/non SHH Group 3, Myc amplification         Autopsy (leptomeningial spread)              3 y ♂                                                      NSG 4--6 weeks                                     Short-term cell culture in spheroids                              Cerebellum (AP −2 mm, DV −2 mm)                                                               \+        33--40 days                            On request (Dr. Cho, Stanford)                                                                                               ([@B65])

  SU-MB-09                                             Medulloblastoma                                             ND                                         Non WNT/non SHH Group 4                            Surgical resection                           9 y ♀                                                      NSG 4--6 weeks                                     Short-term cell culture in spheroids                              Cerebellum (AP −2 mm, DV −2 mm)                                                               \+        83--100 days                           On request (Dr. Cho, Stanford)                                                                                               ([@B65])

  UM-MB1                                               Medulloblastoma, NOS                                        Posterior fossa                            ND                                                 Surgical resection                           4 y ♀                                                      CD1 nu/nu, 4 weeks                                 Short-term adherent cell culture                                  Right cerebral hemisphere (ML +1 mm, AP +2 mm, DV −3.5 mm)                                    --        ND                                     On request                                                                                                                   ([@B44])

  **EMBRYONAL TUMORS---OTHER**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  BT183                                                Embryonal tumor with multilayered rosettes, C19MC-altered   ND                                         C19MC amplification                                ND                                           2 y ♂                                                      NOD/SCID, 6--8 weeks                               Short-term cell culture in spheroids                              Right striatum (ML +2 mm, AP −1 mm, DV −3 mm)                                                 \+        8--45 days                             On request                                                                                                                   ([@B88])

  IC-2664 PNET                                         CNS embryonal tumor, NOS                                    ND                                         ND                                                 Surgical resection                           14 y ♀                                                     Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −3 mm)                                    --        48--76 days                            On request                                                                                                                   ([@B89])

  NCH3602                                              Embryonal tumor with multilayered rosettes, C19MC-altered   Right hemisphere                           C19MC amplification                                Surgical resection (at diagnosis)            2 y                                                        NSG, 6--8 weeks                                    Short-term cell culture in spheroids                              Right striatum (ML +2,5 mm, AP −1 mm, DV −3 mm)                                               \+        ND                                     On request                                                                                                                   ([@B90])

  ncPNET                                               CNS embryonal tumor, NOS                                    Cerebrum (left frontal)                    ND                                                 Surgical resection                           5 y                                                        ND                                                 Short-term adherent cell culture                                  Right cerebral hemisphere (ML +2 mm, AP +2 mm)                                                --        ND                                     Children\'s Brain Tumour Research Centre, Nottingham                                                                         ([@B38])

  ATRT-310FH                                           Atypical teratoid/rhabdoid tumor                            Anterior cranial fossa                     ATRT SHH                                           Surgical resection                           6.1 y ♀                                                    NSG, 6--8 weeks                                    Cell suspension from surgical specimen (serial transplantation)   Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −2 mm)                                    --        33--143 days                           BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B51])

  ATRT-312FH                                           Atypical teratoid/rhabdoid tumor                            Cortex (parietal lobe)                     ATRT MYC                                           ND                                           1.8 y ♂                                                    NSG                                                Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −2 mm)                                    --        40--89 days                            BTRL (Brain Tumor Resource Lab---<https://research.fhcrc.org>)                                                               ([@B72])

  CHLA-06-ATRT                                         Atypical teratoid/rhabdoid tumor                            Posterior fossa                            INI-1 loss                                         Surgical resection (primary tumor)           3 mo ♀                                                     ND                                                 Short-term semi-adherent cell culture                             Right striatum (ML +2 mm, AP −3 mm, DV −3 mm)                                                 --        14--20 days                            ATCC ([www.ATCC.org/](http://www.ATCC.org/)) CCR (childhood cancer repository---[www.cccells.org](http://www.cccells.org))   ([@B55])

  CHLA-266                                             Atypical teratoid/rhabdoid tumor                            posterior fossa                            INI-1 loss                                         Surgical resection (at diagnosis)            2.5 y ♀                                                    NSG 6--8 weeks                                     Short-term adherent cell culture                                  Right cuadate/putamen (ML +2 mm, AP +0.5 mm, DV −3.3 mm)                                      --        40--50 days                            CCR (childhood cancer repository---[www.cccells.org](http://www.cccells.org))                                                ([@B43])

  SU-ATRT-02                                           Atypical teratoid/rhabdoid tumor                            Supratentorial                             ND                                                 Surgical resection (primary tumor)           2 y ♂                                                      NSG 5--6 weeks                                     Short-term cell culture in spheroids                              Right striatum (ML +2 mm, AP −2 mm, DV −3.5 mm)                                               \+        50--63 days                            On request                                                                                                                   ([@B65])

  **GERM CELL TUMORS**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  IC-6999GCT                                           Germinoma                                                   C6 spinal cord                             ND                                                 Surgical resection (metastasis-recurrence)   16 y ♂                                                     Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −3 mm)                                    --        80--242 days                           On request                                                                                                                   ([@B62])

  IC-9320GCT                                           Germinoma                                                   Supratentorial                             KIT D816H                                          Surgical resection (metastasis)              1.5 y ♀                                                    Rag2/SCID, 6--8 weeks                              Cell suspension from surgical specimen                            Right cerebral hemisphere (ML +1 mm, AP +1.5 mm, DV −3 mm)                                    --        60--160 days                           On request                                                                                                                   ([@B62])

  **TUMORS OF THE SELLAR REGION**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  adaCP 1                                              Adamantinomatous craniopharyngeoma                          ND                                         CTNNB1 mutation                                    Surgical resection                           16 y ♀                                                     NSG, 5--8 weeks                                    Tumor tissue                                                      Right cerebral hemisphere (ML +3 mm)                                                          --        ND                                     On request                                                                                                                   ([@B33])

  ACP1                                                 Adamantinomatous craniopharyngeoma                          Sellar region                              CTNNB1 mutation                                    Surgical resection                           9 y ♂                                                      NMRI nu/nu, 5 weeks                                Tumor tissue                                                      Right cerebral hemisphere (ML +3 mm)                                                          --        ND                                     On request                                                                                                                   ([@B34])
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Indicated are the location, classification, and moment of collection of the original tumor sample, patient characteristics, mouse/rat strain used, tumor preparation, and injection site. References concern the first manuscripts describing the model only. To facilitate the choice of appropriate models for the preclinical therapeutic studies, this table also indicates whether the model allows for bioluminescence imaging (BLI), time to tumor growth/euthanasia (as estimated from Kaplan-Meijer curves, unless otherwise indicated), and source where to obtain cells. "On request" refers to the corresponding author of the reference. FL, Fluorescence (MION-Rh); ND, Not described*.
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